Universitätsspital Basel, Eye Clinic
Welcome,         Profile    Billing    Logout  
 3 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scholl, Hendrik PN
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/24
09/24
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/29
12/29
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Recruiting
2
140
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
12/24
03/25
NCT05294978: EyeConic: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
Optical coherence tomography (OCT)
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel
Retinal Dystrophies
12/26
12/26
INTERCEPT-AMD, NCT05698316: A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression

Active, not recruiting
N/A
1000
Europe
Collection of both retrospective and prospective data collection in 3 visits.
Association for Innovation and Biomedical Research on Light and Image, European Vision Institute Clinical Research Network
Age Related Macular Degeneration, Intermediate AMD, Atrophy, Prediction
02/24
04/25
PINNACLE, NCT04269304: Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study -

Active, not recruiting
N/A
429
Europe
University of Southampton, Imperial College London, University of Basel, Medical University of Vienna, University of Michigan, King's College London, University College, London
Age-related Macular Degeneration
06/25
06/25
RUSH1F, NCT04765345: Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

Active, not recruiting
N/A
40
Europe, Canada, US, RoW
Jaeb Center for Health Research, Usher 1F Collaborative, Marjorie C. Adams Foundation, Foundation Fighting Blindness
Retinal Degeneration, Retinitis Pigmentosa, Eye Diseases, Hereditary
06/27
06/27
NCT05218928: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
OCT
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
Retinal Dystrophies
04/22
12/22
Drack, Arlene
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
Harrison, Deborah
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT06125977: Impact of Non-Exudative Type 1 MNV on AMD Progression

Active, not recruiting
N/A
73
US
University of Utah, National Eye Institute (NEI)
Age-Related Macular Degeneration, Neovascularization, Choroidal
08/27
08/27
McCormick, Mary
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
SHORT, NCT04417699: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Completed
2
13
US
TAS 102, Tipiracil hydrochloride, Oxaliplatin, Eloxatin
Providence Health & Services, Taiho Oncology
Rectal Cancer
12/23
02/24
NCT05882695: Study of SPG302 in Healthy Volunteers and ALS Participants

Active, not recruiting
1
112
RoW
SPG302, Placebo
Spinogenix, Novotech (Australia) Pty Limited
Amyotrophic Lateral Sclerosis
05/25
12/25
NCT05249114: Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Active, not recruiting
1
6
US
Cabozantinib, Cabometyx, Lu-177, Lutathera
Providence Health & Services, Exelixis, Advanced Accelerator Applications SA
Neuroendocrine Tumors
12/24
12/26

Download Options